Zhitong Finance App News, Baicheng Pharmaceutical (301096.SZ) announced that Zhejiang Symer Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a drug registration certificate for levetiracetam sustained-release granules approved and issued by the State Drug Administration. This drug is a Class 2.2 improved new drug and is suitable for the additional treatment of partial seizures in patients with epilepsy aged 12 and above. Compared to dosage forms such as ordinary tablets and extended-release tablets that have already been marketed, extended-release granules are more suitable for children and patients with difficulty swallowing, improving patient compliance, and have obvious clinical advantages.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.